Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations

Abstract BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAFV600E mutation, they often eventually diverg...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: S. Vasudevan, E. Flashner-Abramson, Heba Alkhatib, Sangita Roy Chowdhury, I. A. Adejumobi, D. Vilenski, S. Stefansky, A. M. Rubinstein, N. Kravchenko-Balasha
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Accès en ligne:https://doaj.org/article/3fa3ce4bd8c843c780d29b16c0e89e36
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!